

## ADULT AMBULATORY INFUSION ORDER Ocrelizumab (OCREVUS)

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

## ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( $\checkmark$ ) TO BE ACTIVE.

Date:/								
*Please fax a cop following patient	-							
PATIENT INFORMATION				PROVIDER INFORMATION				
Allergies:				Printed Provider's Name:				
Weight: lbs/kg Height:				Signature:				
Diagnosis:				NPI:			_ Date:/	/
ICD-10:				Phone: (_	)		_ Fax: ()	_ <del>-</del>
				Office Ad	ldress:			
				Contact F	Person:			<del></del>
Hep B Result:				Test Date:	/_	_/	□ Сору А	Attached
Has patient had any	immuniz	ations i	n the last 6 wee	eks?	□ Yes		□ No	
PRE-MEDICATIONS:								
Diphenhydramine:		□IV	□ 50mg					
Acetaminophen:	□РО		□ 1000 mg					
Solu-Medrol:		□IV	□ 1000 mg					
Other:								
☐ No Pre-Medicatio	ns							
☐ 30 minutes wait t	ime follow	vina nre	-medications					

LABS:								
□ CBC w/diff	☐ EVERY infusion	□ every OTHER infusion	□ other:					
□ CMP	☐ EVERY infusion	☐ every OTHER infusion	□ other:					
☐ Urine HCG	☐ EVERY infusion	□ every OTHER infusion	□ other:					
☐ Other:	□ EVERY infusion	□ every OTHER infusion	□ other:					
□ No labs needed								
OCREVUS (ocrelizumab) IV Dosage:  □ Initial Dose: 300 mg IV at 0 and 2 weeks.								
☐ Subsequent Infusions: 600 mg in 500 mLs of NS every 6 months. Infuse over 3.5 hours or longer.								
Or								
☐ If no history of previous reaction, may proceed with faster infusion over 2 hours.								
☐ Patient is required to stay for 60-minute observation post infusion.								
☐ Patient is NOT required to stay for observation time.								